Late breaker session

 General hepatology
 Webcasted session

Main Plenary
14 April 2018 16:00 - 18:00


LBO-001 A multicenter, randomized, double-blind, PLB-controlled trial of Galectin-3 inhibitor (GR-MD-02) in patients with NASH cirrhosis and portal hypertension
Naga Chalasani , United States
14 April 2018 16:00 - 16:15

LBO-002 NGM282, an Engineered Analogue of FGF19, Significantly Improves Markers of Bile Acid Synthesis, Hepatic Injury and Fibrosis in PSC Patients: Results of a Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
Gideon Hirschfield , United Kingdom
14 April 2018 16:15 - 16:30

LBO-003 RO7049389, a core protein allosteric modulator, demonstrates robust anti-HBV activity in chronic hepatitis B patients and is safe and well tolerated
Edward Gane , New Zealand
14 April 2018 16:30 - 16:45

LBO-004 Safety, pharmakokinetics and antiviral activity of novel capsid assembly modulator (CAM) JNJ-56136379 (JNJ-6379) in treatment-naive chronic hepatitis B (CHB) patients without cirrhosis
Fabien Zoulim , France
14 April 2018 16:45 - 17:00

LBO-005 The impact of combining Selective Internal Radiation Therapy (SIRT) with sorafenib on overall survival in patients with advanced hepatocellular carcinoma: the SORAMIC trial palliative cohort
Jens Ricke , Germany
14 April 2018 17:00 - 17:15

LBO-006 JKB-121 in Patients with Nonalcoholic Steatohepatitis: A Phase 2 Double Blind Randomized Placebo Control Study
Manal Abdelmalek , United States
14 April 2018 17:15 - 17:30

LBO-007 Early assessment of safety and efficacy of tropifexor, a potent non bile-acid FXR agonist, in patients with primary biliary cholangitis: an interim analysis of an ongoing Phase 2 study.
Christoph Schramm , Germany
14 April 2018 17:30 - 17:45

LBO-008 A phase 3b, open-label, randomized, pragmatic study of glecaprevir/pibrentasvir +/- ribavirin (RBV) for HCV genotype 1 subjects who previously failed an NS5A Inhibitor + sofosbuvir (SOF) therapy
Anna Lok , United States
14 April 2018 17:45 - 18:00